CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
HN9 trial, a Randomized Phase II Study Of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Tremelimumab And Durvalumab In Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), was closed to accrual with 121 of the planned 180 patients randomized.
CCTG BLC5 MAIN-CAV: Phase III Randomized Clinical Trial
The CCTG BLC5 MAIN-CAV international trial is now open in Canada testing the addition of a targeted anti-cancer drug to the usual immunotherapy treatment, in patients with metastatic urothelial cancer (mUC).This trial will test whether the addition of the anti-cancer drug, to the maintenance immunotherapy will or will not improve the patient’s overall survival.
CCTG seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required.
